Publications by authors named "H Moatti"

Claim this Profile
O
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma.
H Moatti, P Brice, M-C Laroque, R Di Blasi, J Wencel

Hematol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.
Cédric Rossi, Guillaume Manson, Amira Marouf, Aurélie Cabannes-Hamy, Emmanuelle Nicolas-Virelizier, Hannah Moatti

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Hodgkin Lymphoma during pregnancy, review of the literature and description of an homogenous expectative attitude associated with excellent outcome.
Joshua Hagège, Lorea Aguinaga, Hannah Moatti, Roberta Di Blasi, Catherine Thieblemont

Crit Rev Oncol Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
Loic Renaud, Juliette Wencel, Arnaud Pagès, Ahmad Al Jijakli, Hannah Moatti

Haematologica· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Periorbital erythema and oedema revealing angioimmunoblastic T cell lymphoma.
Donatienne De Clippele, Laure Frumholtz, Marie-Dominique Vignon-Pennamen, Thierry Molina, Hannah Moatti

Eur J Dermatol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis